RxDoctor Payments Data

Brian Black, DO

Family Medicine · Greencastle, INNPI 1437255239

Payments from drug & device makers

$3,116in general payments, 2019–2025

Across 181 payments — averaging $17.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$499
  • AstraZeneca$382
  • Amgen$378
  • Novo Nordisk$339
  • Lilly USA, LLC$261
  • Exact Sciences$141
  • plus $1K from 23 others

What the payments were for

  • Food & beverage$3,09599%
  • Education$201%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,116 in reported general payments places this provider in the 80th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$83,517
Medicare patients
180
Services billed
1,105

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin192$171,634
FarxigaDapagliflozin Propanediol106$126,915
OzempicSemaglutide84$114,687
Tetrabenazine14$66,288
EliquisApixaban61$59,304
Trelegy ElliptaFluticasone/Umeclidin/Vilanter63$50,653
TrulicityDulaglutide44$49,799
MounjaroTirzepatide37$49,222
XareltoRivaroxaban41$36,731
Combivent RespimatIpratropium/Albuterol Sulfate20$19,620
Breztri AerosphereBudesonide/Glycopyr/Formoterol28$17,624
JanuviaSitagliptin Phosphate16$17,102
Lantus SolostarInsulin Glargine,hum.Rec.Anlog84$14,361
TradjentaLinagliptin24$13,491
Aimovig AutoinjectorErenumab-Aooe12$8,787

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Combivent Respimat, Tradjenta$85$204,744236 claims
AstraZenecaFarxiga, Breztri Aerosphere$382$144,539134 claims
Novo NordiskOzempic$339$114,68784 claims
Lilly USA, LLCTrulicity, Mounjaro$261$99,02181 claims
GSKTrelegy Ellipta$114$50,65363 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$17$1,679237 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Greencastle

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →